MARKETSnap
  • Gainers &
    Losers
  • Most Active &
    More
  • 52-Week
    High/Low
  • P/E
    Ratios
    • Large Caps
    • Absolute
    • Total Market PE
  • Stocks
    Performance
    • Large Caps
    • Absolute
  • Industries
    Performance
    • Industry
    • Sector
  • Dividends
  • 📅 Calendar
    • Earnings Calendar
    • Dividends Calendar
    • Economics Calendar
  • 🔧 Tools
    • 💰 Intrinsic Value Calculator
    • 📈 Compounding Calculator
    • 🤖 Stock Pick Screener
  • More
    • Investment Compounding Calculator
    • Commodities
    • Currencies
    • Economic Indicators
      • Inflation
      • Consumer Sentiment
      • Recession Probability
      • Treasury Rates
      • GDP
GRAL stock logo

GRAL

GRAIL, Inc.

$54.99
1.39
 (2.59%)
[ms_data_label text=’Delayed data’]
Exchange:  NASDAQ
Market Cap:  2.256B
Shares Outstanding:  114.139M
Overview
Earnings
Financials
Valuation
Chart

About The Company

Sector:  Healthcare
Industry:  Medical – Diagnostics & Research
   
CEO:  Robert Ragusa
Full Time Employees:  1000
Address: 
1525 O’Brien Drive
Menlo Park
CA
94025
US
Website:  https://grail.com
GRAIL, Inc., a biotechnology company, focuses on developing technologies for early cancer detection. The company develops Galleri, a screening test for asymptomatic individuals over 50 years of age; and DAC, a diagnostic aid for cancer tests to accelerate diagnostic resolution for patients for whom there is a clinical suspicion of cancer. It is also developing minimal residual disease and other post-diagnostic tests. The company was incorporated in 2015 and is based in Menlo Park, California. GRAIL, Inc. operates as a former subsidiary of Illumina, Inc.

Click to read more…

Revenue Segmentation

MARKETSnap

Log in to continue

Log in to see the complete revenue and geographic breakdown.

Login — it's free

EPS

Historical EPS and analyst estimates in one chart. Log in for the full interactive view and links to detailed estimates.

Log in to continue

Log in for the full EPS chart and links to analyst estimates.

Login — it's free
View full analyst estimates

Earnings Call

Full text

Earnings transcript

Read the complete earnings call transcript.

AI summary

Key takeaways

Short, structured highlights from the call so you can focus on what matters.

2025/05/13 — Q1 quarter 2025

Log in to continue

Log in to read the full transcript and AI-generated earnings summaries.

Login — it's free
Income Statement
Balance Sheet
Cash Flow Statement
Analyst Estimates

Income Statement

Year202320242025
Revenue93,105125,595147,172
Gross Profit-95,611-78,022-62,573
EBITDA-638,219-610,166-377,819
Operating Income-1,515,382-2,189,158-534,163
Net Income-1,465,685-2,027,005-408,351

Log in to continue

Log in to see the income statement and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Balance Sheet

Year202320242025
Total Assets3,913,8142,983,3072,922,015
Total Liabilities267,627479,902344,153
Total Stockholders Equity3,646,1872,503,4052,577,862
Total Debt84,40768,14154,863
Cash and Cash Equivalents97,287214,234249,727

Log in to continue

Log in to see the balance sheet and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Cash Flow Statement

Year202320242025
Operating Cash Flow-595,800-577,156-299,007
Capital Expenditure-12,887-5,2080
Free Cash Flow-608,687-582,364-299,007
Net Income-1,465,685-2,027,0050
Net Change in Cash-144,616116,07139,118

Log in to continue

Log in to see the cash flow statement and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Analyst Estimates

Fiscal Year2030Full AccessFull AccessFull AccessFull Access
Estimated Revenue (Low)441,636.614Full AccessFull AccessFull AccessFull Access
Estimated Revenue (High)517,333.419Full AccessFull AccessFull AccessFull Access
Estimated Revenue (Avg)478,591.875Full AccessFull AccessFull AccessFull Access
Estimated Ebitda (Low)-517,333.419Full AccessFull AccessFull AccessFull Access
Estimated Ebitda (High)-441,636.614Full AccessFull AccessFull AccessFull Access
Estimated Ebitda (Avg)-478,591.875Full AccessFull AccessFull AccessFull Access
Estimated Net Income (Low)-365,728.500Full AccessFull AccessFull AccessFull Access
Estimated Net Income (High)-297,689.219Full AccessFull AccessFull AccessFull Access
Estimated Net Income (Avg)-330,906.157Full AccessFull AccessFull AccessFull Access
Estimated SGA Expense (Low)2,654,336.513Full AccessFull AccessFull AccessFull Access
Estimated SGA Expense (High)3,109,291.531Full AccessFull AccessFull AccessFull Access
Estimated SGA Expense (Avg)2,876,446.039Full AccessFull AccessFull AccessFull Access
Estimated EPS (Avg)-9Full AccessFull AccessFull AccessFull Access
Estimated EPS (High)-8.100Full AccessFull AccessFull AccessFull Access
Estimated EPS (Low)-9.950Full AccessFull AccessFull AccessFull Access
Number of Analysts (Estimated Revenue)3Full AccessFull AccessFull AccessFull Access
Number of Analysts (Estimated EPS)2Full AccessFull AccessFull AccessFull Access

Log in to continue

Log in and subscribe to Full Access to see up to 5 years of analyst estimates.

Login — it's free

(* All numbers are in thousands)

Current Key Metrics

?Revenue
 (TTM)
: 
125.595M  ?P/S
 (TTM)
: 
14.41
?Net Income
 (TTM)
: 
-2027005000  ?P/E
 (TTM)
: 
-5.16
?Enterprise Value
 (TTM)
: 
1.969B  ?EV/FCF
 (TTM)
: 
-6.59
?Dividend Yield
 (TTM)
: 
0  ?Payout Ratio
 (TTM)
: 
0
?ROE
 (TTM)
: 
-0.17  ?ROIC
 (TTM)
: 
-0.15
?Net Debt
 (TTM)
: 
-695329000  ?Debt/Equity
 (TTM)
: 
0.04
?P/B
 (TTM)
: 
0.82  ?Current Ratio
 (TTM)
: 
11.97

Log in to continue

Log in to see all key valuation metrics and ratios for this symbol.

Login — it's free

Forward P/E Ratios

?

Forward P/E (Avg EPS estimate) — log in with Full Access for high/low estimates and the interactive table.

Forward P/E 1YFull AccessFull AccessFull AccessFull Access
N/AFull AccessFull AccessFull AccessFull Access

Log in to continue

Log in with Full Access for forward P/E high/low estimates and the full multi-year table.

Login — it's free

SWOT Analysis

🔒 You are currently logged out

Login

It's free

At what price to buy it? -
Intrinsic Value Calculator

This is an automatic estimate. The most reliable way to know fair value for your own assumptions is to run the calculator below.


Calculate GRAL Intrinsic Value

Common questions about GRAL valuation

Is GRAIL, Inc. (GRAL) overvalued or undervalued right now?

MARKETSnap estimates intrinsic value for GRAIL, Inc. (GRAL) using its proprietary valuation methodology, which incorporates discounted cash flow (DCF) analysis together with long-term earnings and fundamentals assumptions. By comparing intrinsic value to the current market price, long-term investors can see whether the stock screens as potentially overvalued, fairly valued, or undervalued today.

Is GRAL a buy, hold, or sell for long-term investors?

MARKETSnap does not give one-word “buy” or “sell” calls. Instead, it shows whether GRAL trades at a premium or discount to its estimated intrinsic value, how sensitive that value is to growth and margin assumptions, and how the stock fits into a diversified, long-term portfolio so investors can make their own buy, hold, or sell decision.

What is GRAL’s P/E ratio?

You can see GRAL’s trailing P/E (TTM) and forward P/E estimates in the Current Key Metrics and Forward P/E Ratios sections above. The P/E ratio compares the current share price to earnings per share and helps investors gauge valuation relative to earnings.

How is intrinsic value calculated for GRAL?

MARKETSnap uses its own valuation framework—not a generic spreadsheet DCF alone. Future cash flows and earnings are projected, discounted, and combined with MARKETSnap’s methodology so intrinsic value reflects fundamentals and long-term assumptions. You can run your own inputs and see the result using the Intrinsic Value Calculator above.

Is GRAL a good long-term investment?

Whether GRAL fits a long-term portfolio depends on your assumptions about growth, margins, and risk. MARKETSnap provides the metrics, intrinsic value calculator, and SWOT context so you can form your own view rather than rely on a single buy/sell rating.

GRAL

1-day price chart preview. Log in for 1W through 5Y ranges and period tabs.

[ms_data_label text="Daily snapshot"]

2.59
MARKETSnap

Trading Metrics:

[ms_session_rows_unavailable]
Open: [ms_cell_or_dash table='trading_quote' column='open']   Previous Close: [ms_cell_or_dash table='trading_quote' column='previousClose']
Day Low: [ms_cell_or_dash table='trading_quote' column='dayLow']   Day High: [ms_cell_or_dash table='trading_quote' column='dayHigh']
Year Low: 20.44   Year High: 118.84
Price Avg 50: 70.68   Price Avg 200: 66.13
Volume: 791997   Average Volume: 1.244M

Log in to continue

Log in for multi-period charts (1W–5Y), period tabs, and the same layout as members.

Login — it's free
See in Nexus

Relevant news

GRAIL to Present New Data From NHS-Galleri and PATHFINDER 2 at 2026 ASCO Annual Meeting
21-04-2026 16:53
GRAIL to Present New Data From NHS-Galleri and PATHFINDER 2 at 2026 ASCO Annual Meeting
GRAL DROPS ~50% -- REPORTED NUMBERS VS. ACTUAL RESULTS; LEVI & KORSINSKY, LLP INVESTIGATES
25-03-2026 09:00
GRAL DROPS ~50% -- REPORTED NUMBERS VS. ACTUAL RESULTS; LEVI & KORSINSKY, LLP INVESTIGATES
GRAIL Partners With Epic to Broaden Galleri Test Access Across US
08-04-2026 12:26
GRAIL Partners With Epic to Broaden Galleri Test Access Across US
GRAIL Announces Integration of the Galleri® Test into Epic Electronic Health Record Platform to Expand Access Nationwide
07-04-2026 16:01
GRAIL Announces Integration of the Galleri® Test into Epic Electronic Health Record Platform to Expand Access Nationwide
GRAL Investors Have Opportunity to Join GRAIL, Inc. Fraud Investigation with the Schall Law Firm
03-04-2026 15:18
GRAL Investors Have Opportunity to Join GRAIL, Inc. Fraud Investigation with the Schall Law Firm
Cancer Is Striking Earlier -- Superpower and GRAIL Are Partnering to Expand Early Detection
01-04-2026 13:09
Cancer Is Striking Earlier -- Superpower and GRAIL Are Partnering to Expand Early Detection

DISCLAIMER: The stock market data provided on this website is for informational purposes only and is not intended for trading purposes. While we strive to provide accurate and timely information, we cannot guarantee that the information is accurate at the moment it is received or that it will continue to be accurate in the future. We are not responsible for any actions taken based on the information provided on this website. Always consult with a licensed financial professional before making any investment decisions.
Terms of Service

Copyright © 2025 MarketSnap. All rights reserved.

Contact Us

Privacy Policy

Cookie Policy

Terms of Service

Hover Image
MARKETSnap

Market

🇺🇸 United States
  • Gainers & Losers
  • Most Active & More
  • 52-Week High/Low
  • Dividends
    • Large Caps
    • Absolute
    • Total Market PE
    • Large Caps
    • Absolute
    • Industry
    • Sector
    • Earnings Calendar
    • Dividends Calendar
    • Economics Calendar
  • 💰 Stock intrinsic value Calculator
  • 📈 Investment Compounding Calculator
  • 🤖 Stock Pick Screener
  • 📋 Watchlist & Portfolio
    • Commodities
    • Currencies
      • Inflation
      • Consumer Sentiment
      • Recession Probability
      • Treasury Rates
      • GDP
  • Nexus
  • Login Login
  • Profile Profile
  • Watchlists Watchlists
  • My Valuations My Valuations
  • Settings Settings

Media

Watch Listen Read